VOYXACT
VOYXACT (sibeprenlimab-szsi) is indicated for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. This indication received accelerated approval based on the drug's ability to reduce proteinuria, though its impact on long-term kidney function decline has not yet been established. Continued approval for this use may be contingent upon the verification of clinical benefit in confirmatory clinical trials.
How VOYXACT Works
VOYXACT is an antibody that binds to A Proliferation Inducing Ligand (APRIL), which blocks signaling at the B cell maturation antigen (BCMA) and TACI receptors. By inhibiting APRIL, the drug reduces serum levels of galactose-deficient immunoglobulin A1 (Gd-IgA1). This reduction is therapeutically relevant because Gd-IgA1 is a protein implicated in the pathogenesis of IgAN.
Details
- Status
- Prescription
- First Approved
- 2025-11-25
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
VOYXACT Approval History
What VOYXACT Treats
1 indicationsVOYXACT is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Immunoglobulin A Nephropathy
VOYXACT Target & Pathway
ProTarget
A protein highly expressed on malignant plasma cells in multiple myeloma. BCMA-targeted therapies, including CAR-T cells and bispecific antibodies, can eliminate myeloma cells while sparing most normal immune cells.
VOYXACT Competitors
Pro4 other drugs also target BCMA. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (BCMA). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to VOYXACT
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
VOYXACT FDA Label Details
ProIndications & Usage
FDA Label (PDF)VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. VOYXACT is an A Proliferation Inducing Ligand (APRIL) blocker, indicated to reduce proteinuria in adults with prim...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.